ATL-801 | 1000005-71-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: ATL-801
• 英文别名: N-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-pyridin-2-yl]-N-ethyl-nicotinamide；N-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7H-purin-8-yl)pyridin-2-yl]-N-ethylpyridine-3-carboxamide；1-cyclopropyl-3-propyl-8-[6-(N-nicotinoyl-N-ethylamino)-3-pyridyl]xanthine；1-Cyclopropyl-3-propyl-8-(6-(N-nicotinoyl-N-ethylamino)-3-pyridyl)xanthine-
• CAS: 1000005-71-9
• 化学式: C₂₄H₂₅N₇O₃
• 分子量: 459.508
• InChiKey: WULKGVCEOREGQF-UHFFFAOYSA-N

物化性质

• 沸点：
  748.0±70.0 °C(Predicted)
• 密度：
  1.394±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  6

制备方法与用途

ATL-801是一种选择性A2B受体拮抗剂，能够改善小鼠的结肠炎症状【1】。

文献信息

• Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension
  申请人：Belardinelli Luiz

  公开号：US20120003329A1

  公开（公告）日：2012-01-05

  This disclosure relates generally to treating patients having pulmonary hypertension, or symptoms associated therewith, by administering a therapeutically effective amount of an A 2B receptor antagonist to the patient.

  本公开涉及通过向患者施用治疗有效量的A2B受体拮抗剂来治疗患有肺动脉高压或与之相关的症状的患者。
• USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS
  申请人：Belardinelli Luiz

  公开号：US20120258974A1

  公开（公告）日：2012-10-11

  Provided are methods of improving the cardiac condition of post-myocardial infarction (MI) patients and reducing cardiovascular death and hospitalization due to heart failure or arrhythmias, by administering a therapeutically effective amount of an A 2B adenosine receptor antagonist.

  提供了改善心肌梗死后患者的心脏状况、减少心衰或心律失常导致的心血管死亡和住院的方法，即通过给予治疗有效剂量的A2B腺苷受体拮抗剂。
• Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
  申请人：Sitaraman Shanthi V.

  公开号：US20080176845A1

  公开（公告）日：2008-07-24

  The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of A 2B adenosine receptors (ARs).

  本发明涉及一种治疗炎症性肠病的方法，包括给予足量的A2B腺苷受体（ARs）拮抗剂。
• Substituted 8-[6-amino-3-pyridyl]xanthines
  申请人：Wang Guoquan

  公开号：US20080004292A1

  公开（公告）日：2008-01-03

  The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines and pharmaceutical compositions that are selective antagonists of A 2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.

  本发明提供了取代的8-[6-氨基-3-吡啶基]黄嘌呤和选择性A2B腺苷受体（ARs）拮抗剂的制药组合物。这些化合物和组合物可用作药物代理。
• Metal salts and uses thereof
  申请人：Inspirna, Inc.

  公开号：US11174220B2

  公开（公告）日：2021-11-16

  The present invention relates to metal salts of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid which exhibit improved physical properties and stability. The invention also relates to pharmaceutical compositions including an effective amount of the metal salts, as well as methods of treating cancer including administration of a pharmaceutical composition including a salt of the invention to a subject in need thereof.

  本发明涉及 2-[3-[(3R)-3-[[2-氯-3-(三氟甲基)苯基]甲基-(2,2-二苯基乙基)氨基]丁氧基]苯基]乙酸的金属盐，其物理性质和稳定性均有所改善。本发明还涉及包括有效量金属盐的药物组合物，以及治疗癌症的方法，包括向有需要的受试者施用包括本发明盐的药物组合物。